AmpliTech Group Prices $9 Million Registered Direct Offering with Significant Potential Dilution

summarizeSummary

This 424B5 filing details the terms of the $9 million registered direct offering announced on the same day. The offering involves 2.23 million units, each priced at $4.055 and consisting of one common share and two series of rights (Series A exercisable at $5.00, Series B at $6.00). While the unit price is at a premium to the current stock price of $3.695, the offering represents a significant capital raise, equating to over 12% of the company's market capitalization. The potential for substantial dilution is high, with up to 6.69 million new shares (common stock plus shares from exercised rights) representing approximately 29% of current outstanding shares. This marks the second significant capital raise in a short period, following a $9 million rights offering completed on January 14, 2026, highlighting ongoing capital requirements. The proceeds are intended for scaling operations, R&D, and general corporate purposes. Investors should note the immediate and substantial dilution to net tangible book value.

check_boxKey Events

• Registered Direct Offering Priced

  The company priced a registered direct offering of 2.23 million units at $4.055 per unit, raising gross proceeds of $9,042,650.

• Significant Potential Dilution

  Each unit includes one common share and two series of rights (Series A exercisable at $5.00, Series B at $6.00), potentially adding up to 6.69 million shares, representing approximately 29% dilution to current outstanding shares if all rights are exercised.

• Follows Recent Capital Raise

  This offering comes shortly after the company completed a separate $9 million Unit Subscription Rights Offering on January 14, 2026, highlighting ongoing capital requirements.

• Use of Proceeds

  Net proceeds of approximately $8.5 million are earmarked for scaling domestic manufacturing, R&D, vertical integration, strategic partnerships, and general corporate purposes.

auto_awesomeAnalysis

This 424B5 filing details the terms of the $9 million registered direct offering announced on the same day. The offering involves 2.23 million units, each priced at $4.055 and consisting of one common share and two series of rights (Series A exercisable at $5.00, Series B at $6.00). While the unit price is at a premium to the current stock price of $3.695, the offering represents a significant capital raise, equating to over 12% of the company's market capitalization. The potential for substantial dilution is high, with up to 6.69 million new shares (common stock plus shares from exercised rights) representing approximately 29% of current outstanding shares. This marks the second significant capital raise in a short period, following a $9 million rights offering completed on January 14, 2026, highlighting ongoing capital requirements. The proceeds are intended for scaling operations, R&D, and general corporate purposes. Investors should note the immediate and substantial dilution to net tangible book value.